• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. Sep 2001; 49(3): 402–408.
PMCID: PMC1728420

Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma


BACKGROUND AND AIMS—Testing for faecal occult blood has become an accepted technique of non-invasive screening for colorectal neoplasia but lack of sensitivity remains a problem. The aim of this study was to compare the sensitivity and specificity of faecal calprotectin and faecal occult blood in patients with colorectal cancer and colonic polyps.
METHODS—Faecal calprotectin and occult blood were assessed in 62 patients with colorectal carcinoma and 233 patients referred for colonoscopy. The range of normality for faecal calprotectin (0.5-10.5 mg/l) was determined from 96 healthy subjects.
RESULTS—Median faecal calprotectin concentration in the 62 patients with colorectal carcinoma (101 mg/l, 95% confidence interval (CI) 57-133) differed significantly from normal (2.3 mg/l, 95% CI 1.6-5.0) with 90% of patients having elevated levels (normal <10 mg/l) whereas only 36/62 (58%) had positive faecal occult bloods. There was no significant difference in faecal calprotectin levels when considering location or Dukes' staging of tumour. Percentage positivity of faecal occult bloods was significantly higher for Dukes' stage C and D cancers compared with Dukes' A and B. In the colonoscopy group, 29 patients with adenomatous polyps were detected in whom the median faecal calprotectin was 12 mg/l (95% CI 2.9-32). Sensitivity for detection of adenomatous polyps was 55% using the calprotectin method and 10% using faecal occult blood testing. The overall sensitivity and specificity of calprotectin for colorectal cancer and adenomatous polyps as a combined group was 79% and 72%, respectively, compared with a sensitivity and specificity of faecal occult blood of 43% and 92%.
CONCLUSIONS—Faecal calprotectin is a simple and sensitive non-invasive marker of colorectal cancer and adenomatous polyps. It is more sensitive than faecal occult blood tests for detection of colorectal neoplasia at the cost of a somewhat lower specificity.

Keywords: colorectal cancer; faecal occult blood testing; calprotectin

Full Text

The Full Text of this article is available as a PDF (151K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hart AR, Wicks AC, Mayberry JF. Colorectal cancer screening in asymptomatic populations. Gut. 1995 Apr;36(4):590–598. [PMC free article] [PubMed]
  • Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975 Dec;36(6):2251–2270. [PubMed]
  • Morson B. President's address. The polyp-cancer sequence in the large bowel. Proc R Soc Med. 1974 Jun;67(6 Pt 1):451–457. [PMC free article] [PubMed]
  • Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of untreated colonic polyps. Gastroenterology. 1987 Nov;93(5):1009–1013. [PubMed]
  • Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996 Nov 30;348(9040):1467–1471. [PubMed]
  • Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996 Nov 30;348(9040):1472–1477. [PubMed]
  • Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993 May 13;328(19):1365–1371. [PubMed]
  • Ahlquist DA. Fecal occult blood testing for colorectal cancer. Can we afford to do this? Gastroenterol Clin North Am. 1997 Mar;26(1):41–55. [PubMed]
  • Herzog P, Holtermüller KH, Preiss J, Fischer J, Ewe K, Schreiber HJ, Berres M. Fecal blood loss in patients with colonic polyps: a comparison of measurements with 51chromium-labeled erythrocytes and with the Haemoccult test. Gastroenterology. 1982 Nov;83(5):957–962. [PubMed]
  • Macrae FA, St John DJ. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology. 1982 May;82(5 Pt 1):891–898. [PubMed]
  • Macrae FA, St John DJ, Caligiore P, Taylor LS, Legge JW. Optimal dietary conditions for hemoccult testing. Gastroenterology. 1982 May;82(5 Pt 1):899–903. [PubMed]
  • Jaffe RM, Kasten B, Young DS, MacLowry JD. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med. 1975 Dec;83(6):824–826. [PubMed]
  • Jaffe RM, Zierdt W. A new occult blood test not subject to false-negative results from reducing substances. J Lab Clin Med. 1979 May;93(5):879–886. [PubMed]
  • Atkin WS. Flexible sigmoidoscopy as a mass screening tool. Eur J Gastroenterol Hepatol. 1998 Mar;10(3):219–223. [PubMed]
  • Saverymuttu SH, Maltby P, Batman P, Joseph AE, Maxwell D. False positive localisation of indium-111 granulocytes in colonic carcinoma. Br J Radiol. 1986 Aug;59(704):773–777. [PubMed]
  • Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992 Sep;27(9):793–798. [PubMed]
  • Gilbert JA, Ahlquist DA, Mahoney DW, Zinsmeister AR, Rubin J, Ellefson RD. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand J Gastroenterol. 1996 Oct;31(10):1001–1005. [PubMed]
  • Kristinsson J, Røseth A, Fagerhol MK, Aadland E, Schjønsby H, Børmer OP, Raknerud N, Nygaard K. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum. 1998 Mar;41(3):316–321. [PubMed]
  • Røseth AG, Kristinsson J, Fagerhol MK, Schjønsby H, Aadland E, Nygaard K, Roald B. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol. 1993 Dec;28(12):1073–1076. [PubMed]
  • Meling TR, Aabakken L, Røseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol. 1996 Apr;31(4):339–344. [PubMed]
  • Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999 Sep;45(3):362–366. [PMC free article] [PubMed]
  • Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000 Oct;47(4):506–513. [PMC free article] [PubMed]
  • Dale I, Brandtzaeg P, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol. 1985 Jul;84(1):24–34. [PubMed]
  • Allison JE, Feldman R, Tekawa IS. Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting. Ann Intern Med. 1990 Mar 1;112(5):328–333. [PubMed]
  • Frommer DJ, Kapparis A, Brown MK. Improved screening for colorectal cancer by immunological detection of occult blood. Br Med J (Clin Res Ed) 1988 Apr 16;296(6629):1092–1094. [PMC free article] [PubMed]
  • St John DJ, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, Penfold JC. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology. 1993 Jun;104(6):1661–1668. [PubMed]
  • Robinson MH, Marks CG, Farrands PA, Bostock K, Hardcastle JD. Screening for colorectal cancer with an immunological faecal occult blood test: 2-year follow-up. Br J Surg. 1996 Apr;83(4):500–501. [PubMed]
  • Morris DW, Hansell JR, Ostrow JD, Lee CS. Reliability of chemical tests for fecal occult blood in hospitalized patients. Am J Dig Dis. 1976 Oct;21(10):845–852. [PubMed]
  • Stroehlein JR, Fairbanks VF, McGill DB, Go VL. Hemoccult detection of fecal occult blood quantitated by radioassay. Am J Dig Dis. 1976 Oct;21(10):841–844. [PubMed]
  • Doran J, Hardcastle JD. Bleeding patterns in colorectal cancer: the effect of aspirin and the implications for faecal occult blood testing. Br J Surg. 1982 Dec;69(12):711–713. [PubMed]
  • Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990 Sep 29;336(8718):763–765. [PubMed]
  • St John DJ, Young GP, McHutchison JG, Deacon MC, Alexeyeff MA. Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia. Ann Intern Med. 1992 Sep 1;117(5):376–382. [PubMed]
  • Winawer SJ. Screening for colorectal cancer: an overview. Cancer. 1980 Mar 15;45(5 Suppl):1093–1098. [PubMed]
  • Crowley ML, Freeman LD, Mottet MD, Strong RM, Sweeney BF, Brower RA, Sharma SP, Anderson DS. Sensitivity of guaiac-impregnated cards for the detection of colorectal neoplasia. J Clin Gastroenterol. 1983 Apr;5(2):127–130. [PubMed]
  • Lipshutz GR, Katon RM, McCool MF, Mayer B, Smith FW, Duffy T, Melnyk CS. Flexible sigmoidoscopy as a screening procedure for neoplasia of the colon. Surg Gynecol Obstet. 1979 Jan;148(1):19–22. [PubMed]
  • Selby JV, Friedman GD, Quesenberry CP, Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992 Mar 5;326(10):653–657. [PubMed]
  • Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst. 1993 Aug 18;85(16):1311–1318. [PubMed]
  • Müller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med. 1995 Sep 11;155(16):1741–1748. [PubMed]
  • Müller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med. 1995 Dec 15;123(12):904–910. [PubMed]
  • Van Dam J, Bond JH, Sivak MV., Jr Fecal occult blood screening for colorectal cancer. Arch Intern Med. 1995 Dec 11;155(22):2389–2402. [PubMed]
  • Morris JB, Stellato TA, Guy BB, Gordon NH, Berger NA. A critical analysis of the largest reported mass fecal occult blood screening program in the United States. Am J Surg. 1991 Jan;161(1):101–106. [PubMed]

Figures and Tables

Figure 1
Log faecal calprotectin concentration (mg/l) in the different diagnostic groups. Median values with 95% (+) and 5% (-) confidence intervals are shown. All three diagnostic groups differed significantly from controls (normal/irritable bowel syndrome, ...
Figure 2
Receiver operating curve for faecal calprotectin in detecting patients with colorectal neoplasia (carcinoma and adenoma). The curve is statistically significant (p<0.0001) with the area beneath it being greater than 50%, and shows the effect ...

Articles from Gut are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...